EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ADMA Biologics's enterprise value is $2,219.5 Mil.
ADMA Biologics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $28.0 Mil. Therefore, ADMA Biologics's EV-to-EBITDA for today is 79.14.
The historical rank and industry rank for ADMA Biologics's EV-to-EBITDA or its related term are showing as below:
ADMA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -125.9 Med: -4.81 Max: 308.97
Current: 79.14
During the past 13 years, the highest EV-to-EBITDA of ADMA Biologics was 308.97. The lowest was -125.90. And the median was -4.81.
ADMA's EV-to-EBITDA is ranked worse than 91.9% of 457
companies
in the Biotechnology industry
Industry Median: 9.79
vs ADMA: 79.14
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
ADMA Biologics EV-to-EBITDA Historical Data
The historical data trend for ADMA Biologics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ADMA Biologics's EV-to-EBITDA
For the Biotechnology subindustry, ADMA Biologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's EV-to-EBITDA falls into.
ADMA Biologics EV-to-EBITDA Calculation
ADMA Biologics's EV-to-EBITDA for today is calculated as:
ADMA Biologics's current Enterprise Value is $2,219.5 Mil.
ADMA Biologics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $28.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ADMA Biologics's PE Ratio for today is calculated as:
ADMA Biologics's share price for today is $9.10.
ADMA Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of ADMA Biologics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
ADMA Biologics (ADMA Biologics) Business Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADMA has been successfully added to your 